Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1222 participants.

Also called NCT03521934

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,222 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03521934
  • EudraCT 2017-003510-16
Other papers using this trial's data
  • Cost-Effectiveness of Sotagliflozin in SOLOIST-WHF JACC. Heart failure, 2024-09 DOI, PubMed 38878007
  • Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial Annals of internal medicine, 2021-08 DOI, PubMed 34152828
  • Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF Journal of the American College of Cardiology, 2024-09-17 DOI, PubMed 39260929
  • Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure The New England journal of medicine, 2021-01-14 DOI, PubMed 33200892

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Italy, Latvia, Lithuania, Netherlands, New Zealand, Poland, Portugal, Romania, Russia, Slovakia, South Korea, Spain, Sweden, Switzerland, Türkiye, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03521934. Randomized; quadruple masking; primary purpose treatment. Start 2018-06-15 (actual); primary completion 2020-06-05 (actual). Results posted on 2022-10-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
Condition
Heart Failure
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Sotagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Lexicon Pharmaceuticals (class: industry)
Collaborator
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct03521934
Content hash
61da770167e60200a7f8f69761312c6d663026d837fd1b130272444b5cf7cdc0